University of Nottingham
  • Print

Core Outcomes for eczema trials

The four core outcome domains that should be measured and reported in ALL eczema trials are:

  1. Clinician-reported signs
  2. Patient-reported symptoms
  3. Quality of Life
  4. Long-term control

All trials should measure the core domains and measure these using core outcome instruments (where available) as this will enable trials to be compared and combined in meta-analyses. However, the inclusion of core outcomes does not preclude the use of any additional domains, scales or instruments.

Clinical Signs - EASI

For clinical signs

 Consensus Statement: Schmitt et al. 2014

Eczema Area and Severity Index (EASI) is a validated scoring system that grades the physical signs of atopic dermatitis/eczema.

Patient-Reported Symptoms - POEM

For patient reported symptoms

 Consensus Statement:  Spuls et al. 2017

Patient Oriented Eczema Measure (POEM) is a validated instrument that measures the illness as experienced by the patient. 


Quality of Life

Quality of Life

Work is ongoing to identify suitable instruments for quality of life (QoL).

HOME has assessed currently available instruments for adults and children. No instrument(s) were identified that could be recommended for the COS.

Long-Term Control

Long-term Control

Long-term control should be captured by repeated measurement of the other 3 domains (signs, symptoms and QoL).

Work is ongoing to develop a patient global assessment to measure long term control.


HOME - Harmonising Outcome Measures for Eczema

Centre of Evidence Based Dermatology
University of Nottingham
King's Meadow Campus
Lenton Lane, Nottingham

Telephone: +44 115 8232435
Fax: +44 115 8468618